In this study, NPQ-C6, a novel NPQ-coumarin hybrid compound, was shown to inhibit BCR-ABL1/STAT5/c-MYC/PIM-1 oncogenic pathway in both IM-sensitive and IM-resistant CML. This evidence concerns the gene STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive.